Key Documents

View All Documentation

Fluconazole solution

Name: Fluconazole solution
Brand: CERILLIAN

2.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant^®

Select a Size

Change View

Pack Size	SKU	Availability	Price

About This Item

Empirical Formula (Hill Notation):

C₁₃H₁₂F₂N₆O

CAS Number:

86386-73-4

Molecular Weight:

306.27

UNSPSC Code:

41116107

PubChem Substance ID:

329799654

EC Number:

200-659-6

NACRES:

NA.24

MDL number:

MFCD00274549

Pricing and availability is not currently available.

Technical Service

Need help? Our team of experienced scientists is here for you.

Let Us Assist

Properties

grade

certified reference material

Quality Level

300

form

liquid

feature

(Snap-N-Spike^®)

packaging

ampule of 1 mL

manufacturer/tradename

Cerilliant^®

concentration

2.0 mg/mL in methanol

technique(s)

gas chromatography (GC): suitable, liquid chromatography (LC): suitable

application(s)

clinical testing

format

single component solution

storage temp.

−20°C

SMILES string

Fc1c(ccc(c1)F)C(O)(C[n]3ncnc3)C[n]2ncnc2

InChI

1S/C13H12F2N6O/c14-10-1-2-11(12(15)3-10)13(22,4-20-8-16-6-18-20)5-21-9-17-7-19-21/h1-3,6-9,22H,4-5H2

InChI key

RFHAOTPXVQNOHP-UHFFFAOYSA-N

Description

General description

Fluconazole, sold under trade names such as Trican, Monicure, Diflucan^®, and Afungil, is an antifungal drug used in the treatment and prevention of superficial and systemic fungal infections. This Certified Spiking Solution^® is suitable as starting material for calibrators, controls, or linearity standards for therapeutic drug monitoring or clinical and diagnostic testing of fluconazole in patient blood, serum, or plasma samples by HPLC or LC-MS/MS.

Legal Information

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany

CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation

Diflucan is a registered trademark of Pfizer, Inc.

Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

Compare Similar Items

View Full Comparison

Show Differences

1 of 1

This Item	Y0000557	1271700	BP1174
Supelco F-031 Fluconazole solution	Y0000557 Fluconazole	USP 1271700 Fluconazole	BP1174 Fluconazole
grade certified reference material	grade pharmaceutical primary standard	grade pharmaceutical primary standard	grade pharmaceutical primary standard
format single component solution	format neat	format neat	format neat
concentration 2.0 mg/mL in methanol	concentration -	concentration -	concentration -
packaging ampule of 1 mL	packaging -	packaging -	packaging -
feature (Snap-N-Spike^®)	feature -	feature -	feature -
technique(s) gas chromatography (GC): suitable, liquid chromatography (LC): suitable	technique(s) -	technique(s) -	technique(s) -

Still not finding the right product?

Explore all of our products under Fluconazole solution

pictograms

GHS02,GHS06,GHS08

signalword

Danger

hcodes

H225,H301 + H311 + H331,H370

pcodes

P210 - P233 - P280 - P301 + P310 - P303 + P361 + P353 - P304 + P340 + P311

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

target_organs

Eyes,Central nervous system

Storage Class

3 - Flammable liquids

wgk

WGK 2

flash_point_f

49.5 °F - closed cup

flash_point_c

9.7 °C - closed cup

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Pharmacokinetic evaluation of fluconazole in critically ill patients.

Mahipal Sinnollareddy et al.

Expert opinion on drug metabolism & toxicology, 7(11), 1431-1440 (2011-09-03)

Invasive candidiasis has emerged over the last few decades as an increasingly important nosocomial problem for the critically ill, affecting around 2% of intensive care unit patients. Although poor outcomes associated with invasive candidiasis among critically ill patients may relate

Candida tropicalis: its prevalence, pathogenicity and increasing resistance to fluconazole.

Rajendra J Kothavade et al.

Journal of medical microbiology, 59(Pt 8), 873-880 (2010-04-24)

Candida tropicalis has been identified as the most prevalent pathogenic yeast species of the Candida-non-albicans group. Historically, Candida albicans has been the major species responsible for causing candidiasis in immunocompromised and immunocompetent patients. However, infections (candidiasis) due to C. tropicalis

Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: time for harmonization of CLSI and EUCAST broth microdilution methods.

M A Pfaller et al.

Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy, 13(6), 180-195 (2010-11-06)

Both the Clinical and Laboratory Standards Institute (CLSI) and the European Committee on Antimicrobial Susceptibility Testing (EUCAST) have MIC clinical breakpoints (CBPs) for fluconazole (FLU) and Candida. EUCAST CBPs are species-specific, and apply only to C. albicans, C. tropicalis and

View All Related Papers

Global Trade Item Number

SKU	GTIN
F-031-1ML	04061833610282

Questions

Reviews

No rating value